

Mainstay Medical to present at Innovation in Medtech Dublin 2016 Conference

DUBLIN--([BUSINESS WIRE](#))-- Regulatory News:

Mainstay Medical International plc (**Mainstay** or the **Company**, Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8[®], an implantable neurostimulation system to treat disabling Chronic Low Back Pain, announces that Peter Crosby, Chief Executive Officer, is to present at the Innovation in Medtech Dublin 2016 Conference, to be held on 12 – 14 April 2016 at The Shelbourne Hotel in Dublin, Ireland.

Mr. Crosby will present on Wednesday 13 April from 9.00am BST. The presentation will be made available on the Company's website shortly after the meeting at: <http://www.mainstay-medical.com/investors/presentations>.

In addition, Peter Crosby, Chief Executive Officer, and Hugh Kavanagh, Chief Financial Officer, will attend the 9th Kempen Life Sciences Conference in Amsterdam on Thursday 7 April 2016.

If you would like to meet with Mainstay management at either of these events, please contact the event organizers or investor-relations@mainstay-medical.com

- End -

About Mainstay

Mainstay is a medical device company focused on bringing to market an innovative implantable neurostimulation system, ReActiv8[®], for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States and Australia, and is listed on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).

About Chronic Low Back Pain (CLBP)

One of the recognised root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilise the spine in the lower back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.

People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilisation put a significant burden on individuals, families, communities, industry, and governments.

Further information can be found at www.mainstay-medical.com

ReActiv8 is an investigational device and is not approved for commercialization anywhere in the world.

CAUTION – in the United States, ReActiv8 is limited by federal law to investigational use only

Contacts

Mainstay Medical
PR and IR Enquiries:
Consilium Strategic Communications (international strategic communications – business and trade media)
Chris Gardner, Mary-Jane Elliott, Jessica Hodgson, Hendrik Thys

Tel: +44 203 709 5700 / +44 7921 697 654
Email: mainstaymedical@consilium-comms.com

or

FTI Consulting (for Ireland)

Jonathan Neilan

Tel: +353 1 663 3686

Email: jonathan.neilan@fticonsulting.com

or

FTI Consulting (for France)

Astrid Villette

Tel: +33 1 47 03 69 51

Email: Astrid.Villette@fticonsulting.com

or

Investor Relations:

The Trout Group LLC

Jillian Connell

Tel: +1 646 378 2956 / +1 617 309 8349

Email: jconnell@troutgroup.com

or

ESM Advisers:

Fergal Meegan or Barry Murphy, Davy

Tel: +353 1 679 6363

Email: fergal.meegan@davy.ie or

barry.murphy2@davy.ie

Source: Mainstay Medical